immunoglobulin therapy - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.15 [0.00, 4.77]< 182%3 studies (3/-)85.6 %lownot evaluable highcrucial-
deaths 0.15 [0.00, 4.77]< 182%3 studies (3/-)85.6 %lownot evaluable highcrucial-
mechanical ventilation 1.49 [0.59, 3.78]< 10%1 study (1/-)20.1 %NAnot evaluable important-
radiologic improvement (14-day) 2.33 [0.45, 12.00]> 10%1 study (1/-)84.4 %NAnot evaluable important-
viral clearance 36.42 [10.85, 122.18]> 10%1 study (1/-)100.0 %NAnot evaluable important-
viral clearance by day 14 36.42 [10.85, 122.18]> 10%1 study (1/-)100.0 %NAnot evaluable important-
ICU admission 0.56 [0.18, 1.74]< 10%1 study (1/-)84.3 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.49 [0.02, 15.10]< 10%1 study (1/-)65.4 %NAnot evaluable important-
adverse events 1.36 [0.56, 3.30]< 10%1 study (1/-)25.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.